Assessment and process optimization of high throughput biofabrication of immunocompetent breast cancer model for drug screening applications.
Priyanshu ShuklaAshis Kumar BeraAmit GhoshKiranmai GaddamFalguni PatiPublished in: Biofabrication (2024)
Recent advancements in 3D cancer modeling have significantly enhanced our ability to delve into the intricacies of carcinogenesis. Despite the pharmaceutical industry's substantial investment of both capital and time in the drug screening and development pipeline, a concerning trend persists: drug candidates screened on conventional cancer models exhibit a dismal success rate in clinical trials. One pivotal factor contributing to this discrepancy is the absence of drug testing on pathophysiologically biomimetic 3D cancer models during pre-clinical stages. Unfortunately, current manual methods of 3D cancer modeling, such as spheroids and organoids, suffer from limitations in reproducibility and scalability. In our study, we have meticulously developed 3D bioprinted breast cancer model utilizing decellularized adipose tissue-based hydrogel obtained via a detergent-free decellularization method. Our innovative printing techniques allows for rapid, high-throughput fabrication of 3D cancer models in a 96-well plate format, demonstrating unmatched scalability and reproducibility. Moreover, we've conducted extensive validation, showcasing the efficacy of our platform through drug screening assays involving two potent anti-cancer drugs, 5-Fluorouracil and PRIMA-1Met. Notably, our platform facilitates effortless imaging and gene expression analysis, streamlining the evaluation process. In a bid to enhance the relevance of our cancer model, we've introduced a heterogeneous cell population into the DAT-based bioink. Through meticulous optimization and characterization, we've successfully developed a biomimetic immunocompetent breast cancer model, complete with microenvironmental cues and diverse cell populations. This breakthrough paves the way for rapid multiplex drug screening and the development of personalized cancer models, marking a paradigm shift in cancer research and pharmaceutical development.
Keyphrases
- papillary thyroid
- high throughput
- squamous cell
- adipose tissue
- clinical trial
- lymph node metastasis
- type diabetes
- randomized controlled trial
- squamous cell carcinoma
- metabolic syndrome
- bone marrow
- insulin resistance
- mesenchymal stem cells
- drug induced
- young adults
- transcription factor
- copy number
- extracellular matrix
- bone regeneration